{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T08:11:27Z","timestamp":1778227887785,"version":"3.51.4"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["REN-181675"],"award-info":[{"award-number":["REN-181675"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020951","name":"Fonds de recherche du Qu\u00e9bec","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020951","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000245","name":"Michael Smith Health Research BC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000245","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010658","name":"St. Paul's Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010658","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.cct.2025.107916","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T09:15:33Z","timestamp":1744622133000},"page":"107916","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A protocol for high-dose lisdexamfetamine and contingency management, alone or in combination, for the treatment of methamphetamine use disorder: The ASCME study"],"prefix":"10.1016","volume":"153","author":[{"given":"Paxton","family":"Bach","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Le Foll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"de Kiewit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamzah","family":"Bakouni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ginette","family":"Poulin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monty","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Didier","family":"Jutras-Aswad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.cct.2025.107916_bb0005","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1177\/07067437231158933","article-title":"Amphetamine-related emergency department visits in Ontario, Canada, 2003-2020","volume":"68","author":"Crispo","year":"2023","journal-title":"Can. J. Psychiatr."},{"issue":"12","key":"10.1016\/j.cct.2025.107916_bb0010","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1111\/add.16318","article-title":"Charting the fourth wave: geographic, temporal, race\/ethnicity and demographic trends in polysubstance fentanyl overdose deaths in the United States, 2010-2021","volume":"118","author":"Friedman","year":"2023","journal-title":"Addiction"},{"issue":"4","key":"10.1016\/j.cct.2025.107916_bb0015","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2105\/AJPH.2019.305527","article-title":"Resurgent methamphetamine use at treatment admission in the United States, 2008-2017","volume":"110","author":"Jones","year":"2020","journal-title":"Am. J. Public Health"},{"key":"10.1016\/j.cct.2025.107916_bb0020","doi-asserted-by":"crossref","unstructured":"V.S. Tardelli, S. Johnstone, B. Xu, S. Kim, K. K. H. D. Gratzer, T.P. George, B. Le Foll, D.J. Castle, Marked Increase in Amphetamine-Related Emergency Department Visits and Inpatient Admissions in Toronto, Canada, 2014\u20132021, Canadian journal of psychiatry. 68(4) (2023) 249\u2013256.","DOI":"10.1177\/07067437221125302"},{"issue":"6","key":"10.1016\/j.cct.2025.107916_bb0025","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.3758","article-title":"Evaluation of amphetamine-related hospitalizations and associated clinical outcomes and costs in the United States","volume":"1","author":"Winkelman","year":"2018","journal-title":"JAMA Netw. Open"},{"issue":"4","key":"10.1016\/j.cct.2025.107916_bb0030","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s40263-020-00711-x","article-title":"Pharmacological treatment of methamphetamine\/amphetamine dependence: a systematic review","volume":"34","author":"Siefried","year":"2020","journal-title":"CNS Drugs"},{"issue":"6","key":"10.1016\/j.cct.2025.107916_bb0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0234809","article-title":"Treatment of stimulant use disorder: a systematic review of reviews","volume":"15","author":"Ronsley","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.cct.2025.107916_bb0040","series-title":"The ASAM\/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder","article-title":"T. Wiegand","author":"Batki","year":"2023"},{"key":"10.1016\/j.cct.2025.107916_bb0045","article-title":"Psychosocial interventions for stimulant use disorder","volume":"2","author":"Minozzi","year":"2024","journal-title":"Cochrane Database Syst. Rev."},{"issue":"12","key":"10.1016\/j.cct.2025.107916_bb0050","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1111\/add.14755","article-title":"Pharmacotherapy for methamphetamine\/amphetamine use disorder-a systematic review and meta-analysis","volume":"114","author":"Chan","year":"2019","journal-title":"Addiction"},{"issue":"2","key":"10.1016\/j.cct.2025.107916_bb0055","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/add.16347","article-title":"Prescription psychostimulants for the treatment of amphetamine-type stimulant use disorder: a systematic review and meta-analysis of randomized placebo-controlled trials","volume":"119","author":"Sharafi","year":"2024","journal-title":"Addiction"},{"issue":"8","key":"10.1016\/j.cct.2025.107916_bb0060","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1007\/s00213-020-05563-3","article-title":"Prescription psychostimulants for the treatment of stimulant use disorder: a systematic review and meta-analysis","volume":"237","author":"Tardelli","year":"2020","journal-title":"Psychopharmacology"},{"issue":"5","key":"10.1016\/j.cct.2025.107916_bb0065","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1017\/S1092852900027541","article-title":"Lisdexamfetamine dimesylate: a prodrug stimulant for the treatment of ADHD in children and adults","volume":"15","author":"Mattingly","year":"2010","journal-title":"CNS Spectr."},{"issue":"5","key":"10.1016\/j.cct.2025.107916_bb0070","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-044696","article-title":"Safety and tolerability of oral lisdexamfetamine in adults with methamphetamine dependence: a phase-2 dose-escalation study","volume":"11","author":"Ezard","year":"2021","journal-title":"BMJ Open"},{"issue":"5","key":"10.1016\/j.cct.2025.107916_bb0075","doi-asserted-by":"crossref","DOI":"10.1111\/add.16409","article-title":"Reduced drug use as an alternative valid outcome in individuals with stimulant use disorders: findings from 13 multisite randomized clinical trials","volume":"119","author":"Amin-Esmaeili","year":"2024","journal-title":"Addiction"},{"issue":"1","key":"10.1016\/j.cct.2025.107916_bb0080","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/add.14289","article-title":"What defines a clinically meaningful outcome in the treatment of substance use disorders: reductions in direct consequences of drug use or improvement in overall functioning?","volume":"114","author":"Kiluk","year":"2019","journal-title":"Addiction"},{"key":"10.1016\/j.cct.2025.107916_bb0085","series-title":"Handbook of Psychiatric Measures","article-title":"Alcohol timeline Followback (TLFB)","author":"Sobell","year":"2000"},{"issue":"1","key":"10.1016\/j.cct.2025.107916_bb0090","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1037\/0022-006X.68.1.134","article-title":"The timeline followback reports of psychoactive substance use by drug-abusing patients: psychometric properties","volume":"68","author":"Fals-Stewart","year":"2000","journal-title":"J. Consult. Clin. Psychol."},{"issue":"6","key":"10.1016\/j.cct.2025.107916_bb0095","doi-asserted-by":"crossref","first-page":"774","DOI":"10.15288\/jsa.2004.65.774","article-title":"Temporal stability of the timeline followback interview for alcohol and drug use with psychiatric outpatients","volume":"65","author":"Carey","year":"2004","journal-title":"J. Stud. Alcohol"},{"issue":"1","key":"10.1016\/j.cct.2025.107916_bb0100","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1186\/s12874-020-01167-9","article-title":"Statistical methods for the analysis of adverse event data in randomised controlled trials: a scoping review and taxonomy","volume":"20","author":"Phillips","year":"2020","journal-title":"BMC Med. Res. Methodol."},{"issue":"7","key":"10.1016\/j.cct.2025.107916_bb0105","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-020723","article-title":"LiMA: a study protocol for a randomised, double-blind, placebo controlled trial of lisdexamfetamine for the treatment of methamphetamine dependence","volume":"8","author":"Ezard","year":"2018","journal-title":"BMJ Open"},{"issue":"9","key":"10.1016\/j.cct.2025.107916_bb0110","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.34540","article-title":"Buprenorphine dose and time to discontinuation among patients with opioid use disorder in the era of fentanyl","volume":"6","author":"Chambers","year":"2023","journal-title":"JAMA Netw. Open"},{"issue":"6","key":"10.1016\/j.cct.2025.107916_bb0115","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1093\/aje\/kwp186","article-title":"Proportional hazards frailty models for recurrent methadone maintenance treatment","volume":"170","author":"Nosyk","year":"2009","journal-title":"Am. J. Epidemiol."},{"issue":"12","key":"10.1016\/j.cct.2025.107916_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002715","article-title":"Comparative efficacy and acceptability of psychosocial interventions for individuals with cocaine and amphetamine addiction: a systematic review and network meta-analysis","volume":"15","author":"De Crescenzo","year":"2018","journal-title":"PLoS Med."},{"issue":"6","key":"10.1016\/j.cct.2025.107916_bb0125","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/dar.12194","article-title":"Solving the problem of non-attendance in substance abuse services","volume":"33","author":"Milward","year":"2014","journal-title":"Drug Alcohol Rev."},{"issue":"12","key":"10.1016\/j.cct.2025.107916_bb0130","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s40263-014-0209-8","article-title":"Methamphetamine psychosis: epidemiology and management","volume":"28","author":"Glasner-Edwards","year":"2014","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.cct.2025.107916_bb0135","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1001\/jamapsychiatry.2023.4294","article-title":"Attention-deficit\/hyperactivity disorder medications and long-term risk of cardiovascular diseases","volume":"81","author":"Zhang","year":"2024","journal-title":"JAMA Psychiatry"}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714425001107?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714425001107?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T07:21:09Z","timestamp":1778224869000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714425001107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":27,"alternative-id":["S1551714425001107"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2025.107916","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A protocol for high-dose lisdexamfetamine and contingency management, alone or in combination, for the treatment of methamphetamine use disorder: The ASCME study","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2025.107916","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107916"}}